D
espite major advances in cardiovascular prevention and care, 1 heart disease-primarily caused by atherosclerosis-remains the leading cause of death in the United States 2 and is increasing throughout the world. 3, 4 Because of the central role of plasma-derived lipids (especially low-density lipoprotein cholesterol [LDL-C]) in atherosclerosis, current medical therapies for atherosclerosis (eg, statins, ezetemibe, and evolucumab) are aimed primarily at lowering plasma LDL-C. These therapies reduce major adverse cardiovascular events 5 ; however, they have not eliminated them. For example, lowering plasma LDL-C <70 mg/dL in postinfarction patients only marginally (≈25%) decreased event rates during 30-month follow-up. 6 Addition of evolucumab to statin therapy reduced LDL-C from a median of 92 to 30 mg/dL but lowered cardiovascular events by only 14% compared with placebo. 7 The limits of LDL-C-lowering are at hand; however, atherosclerosis-associated morbidity and mortality remain high. In addition to therapies that lower plasma LDL-C, an alternative strategy aims to treat atherosclerosis by removing cholesterol from the blood vessel wall. This strategy was initially aimed at increasing plasma high-density lipoprotein cholesterol (HDL-C) because HDL-C was thought to be the primary mediator of reverse cholesterol transport, the endogenous process through which cholesterol is removed from tissues and transported to the liver for excretion. 8 However, when added to statin therapy, pharmacological agents that increase plasma HDL in humans (including niacin and CETP [cholesteryl ester transfer protein] inhibitors) have not reduced cardiovascular events. [9] [10] [11] Related therapeutic approaches include efforts to increase plasma levels of apo A-I (apolipoprotein A-I; the most abundant protein in HDL-C) 12 by (1) infusion of apo A-I protein, complexed with lipid to extend plasma half-life; (2) delivery of small molecules that mimic the function of apo A-I; or (3) use of drugs that enhance the function of plasma HDL. These approaches have shown promise in animal models and small human trials [13] [14] [15] [16] [17] but have not yet shown clinical benefit in larger human trials. [18] [19] [20] Moreover, lifetime injections of apo A-I protein or apo A-I-mimetic peptides would be both expensive and impractical.
; and (3) gene therapy has the potential to persist indefinitely, [24] [25] [26] [27] meaning that one treatment could provide lifetime protection. We previously showed that apo A-I vascular gene therapy retarded development of intimal fatty streaks in carotid arteries of fat-fed rabbits. 22 However, the small size and self-limited nature of the lesions and the brief duration of the therapeutic effect (4 weeks) left it uncertain whether apo A-I gene therapy could have durable effects and whether it could prevent development of more complex lesions. It was also unknown whether helper-dependent adenoviral (HDAd) vector would durably express a transgene in an atherosclerotic milieu, in which endothelial injury and increased endothelial cell (EC) turnover 28, 29 could lead to loss of vector genomes and transgene expression. To be clinically useful, apo A-I vascular gene therapy will need to be effective far longer than 4 weeks and will need to prevent growth of complex lesions, not only fatty streaks. Here, we test whether an apo A-I-expressing vector (HDAdApoAI), delivered to carotid arteries of hyperlipidemic rabbits, can continue to express apo A-I and prevent atherosclerotic lesion growth 24 weeks after treatment.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Rabbit Response to Atherogenic Diet
Four weeks of high-cholesterol diet elevated plasma cholesterol levels in all of the 27 rabbits initially enrolled. As expected, 30, 31 the rabbits' response was highly variable, with plasma cholesterols ranging from 200 to >2700 mg/dL ( Figure I in the onlineonly Data Supplement). After vector infusion, each rabbit's diet was adjusted every 2 weeks based on measurements of plasma cholesterol, with a goal of maintaining plasma cholesterol levels within a range of 200 to 800 mg/dL. This range promotes robust atherosclerotic lesion development within 24 weeks, is well tolerated, 30, 31 and avoids toxicity associated with an invariant highcholesterol diet. 32 In this study, only 2 rabbits developed signs of dietary toxicity, evidenced by high plasma cholesterol levels and inappetence. Both rabbits regained their appetites after switching to normal chow, and their plasma cholesterol levels dropped into the target range. At the time of vector infusion (HDAdApoAI in one common carotid and control vector [HDAdNull] in the contralateral carotid), plasma cholesterol was 1273±537 mg/dL. At harvest, 24 weeks later, plasma cholesterol was 565±162 mg/dL. Twenty-five of 27 rabbits completed the study (Materials and Methods in the online-only Data Supplement). Common carotid arteries were removed and processed as illustrated in Figure II in the online-only Data Supplement.
Persistence of HDAd Genomes and Apo A-I Expression in HDAdApoAI-Transduced Arteries
We measured vector genomes in 50 arteries, harvested 24 weeks after vector infusion. Vector genomes were detected in all arteries, with no difference between HDAdNull-and HDAdApoAIinfused arteries (P=0.4). Artery extracts contained a median of 2.0 (1.5-3.2) vector genomes per vascular wall cell ( Figure 1A ). Our gene transfer protocol, using adenoviral vectors incubated in the carotid lumen, limits transduction essentially to a single layer of luminal ECs, [33] [34] [35] which constitute ≈9% of total vascular cells (Figure 2 and data not shown). Therefore, 24 weeks after transduction, each EC seems to retain ≈22 copies of the HDAd vector genome. Apo A-I mRNA was near background in all HDAdNull-transduced carotid arteries ( Figure 1B ). In contrast, apo A-I mRNA was easily detectable in 25 out of 25 (100%) of HDAdApoAI-transduced carotids, with a median level of apo A-I mRNA >380-fold above the median polymerase chain reaction signal in HDAdNull-transduced carotids (P<0.001; Figure 1B ). To detect vector-derived apo A-I protein, transduced artery segments were washed (with a goal of removing plasma-derived apo A-I), placed in explant culture, and the conditioned medium assessed by Western blot. Low levels of apo A-I protein were detected in conditioned medium from only a few of the artery segments: 3 of 25 HDAdApoAIinfused arteries and 3 of 25 HDAdNull-infused arteries. We also measured plasma apo A-I protein by Western blotting of plasma of 8 rabbits, using paired samples (ie, both plasma samples from the same rabbit) obtained immediately before gene transfer and during artery harvest 24 weeks later. During this interval, plasma apo A-I levels declined ≈40% (P=0.007; Figure III in the online-only Data Supplement).
HDAdApoAI Decreases Intimal Area, Medial
Area, Medial Thickness, Intimal:Medial Area Ratio, and Percent Luminal Stenosis All arteries had intimal lesions (Figure 2 ). Intimal lesion size was highly variable, ranging from 1300 to 810,000 µm 2 ( Figure 3A) . As in our other rabbit studies, 22 Figure 3A ; Table) . Paired analyses showed a median 30% smaller intimal area in HDAdApoAI-treated carotids compared with their contralateral HDAdNull-treated carotids (P=0.03; Table) . Median medial area was also reduced by a small amount (9%) in the group of HDAdApoAI-treated carotid arteries, with the paired analyses also showing a slight but statistically significant decrease in medial area in the HDAdApoAI-treated carotids (3% reduction; P=0.02; Figure 3B ). Intimal:medial area ratios were reduced for both the group of HDAdApoAI-treated carotids (48% reduction) and in the paired analyses (29% reduction; P=0.04; Figure 3C ).
Medial area could be reduced by thinning, potentially accompanied by inward or outward remodeling. There was only a small difference in area within the internal elastic lamina between the 2 groups (5%) and essentially no difference in the paired analyses (1% difference; P=0.9; Figure 3D ; Table) . Therefore, the small (3%; P=0.02) reduction in medial area in HDAdApoAI-treated carotids is not associated with arterial remodeling. Rather, the lower medial area in HDAdApoAI-treated carotids is due only to decreased medial thickness (P=0.01; Figure 3E ; Table) . Relevant to this, examination of histological sections revealed modestly increased medial thickness adjacent to large intimal lesions (Figure 2A ), suggesting that thinner medias in HDAdApoAI-treated carotids were a consequence of smaller intimal lesions. Because area within the internal elastic lamina was unchanged between the groups (and medial area was not), in order to most appropriately normalize intimal area to vessel size, we calculated percent luminal stenosis (luminal stenosis=intimal area/area within internal elastic lamina), in addition to calculating the intimal:medial area ratios. The median percent luminal stenosis was reduced by 50% in the group of HDAdApoAI-treated carotid arteries compared with the group of HDAdNulltreated arteries. There was a median 29% decrease in the HDAdApoAI-treated carotids compared with their contralateral controls (P=0.03; Figure 3F ; Table) .
HDAdApoAI Decreases Intimal Lipid, Macrophage, and Smooth Muscle Area
The intimal lesions not only were rich in lipid and macrophages ( Figure 2B , 2C, 2F, and 2G) but also contained significant numbers of smooth muscle cells (SMC), as judged by spindle-shaped cell morphology and staining for muscle actin ( Figure 2D and 2H). In the group of HDAdApoAItreated arteries, median intimal lipid content (Oil Red O) decreased 71% relative to the group of HDAdNull arteries (Table) . Paired analyses also showed lower intimal lipid in HDAdApoAI-treated carotids compared with their contralateral HDAdNull-treated controls in 15 of 25 rabbits, with a median decrease of 23% (P=0.05; Figure 4A ; Table) . The reduction in lipid content was accompanied by a 76% reduction in median intimal macrophage area (RAM-11-stained area) in the group of HDAdApoAI-treated carotids (Table) . Paired analyses showed lower intimal macrophage content in HDAdApoAI-treated carotids compared with contralateral HDAdNull-treated controls in 17 of 25 rabbits, with a median decrease of 32% (P=0.03; Figure 4B ; Table) . SMC content of the intima was also decreased in the group of HDAdApoAI-treated carotids versus the group of HDAdNull-treated controls (60% ; Table) . In the paired analyses, HDAdApoAI treatment decreased SMC content in 18 of the 25 rabbits, with a median decrease of 31% (P=0.02; Figure 4C ; Table) . Rare T cells were present in the intimal lesions in both groups ( Figure 2K , 2L, 2O, and 2P). Although there was a large difference in median intimal content of T cells between the 2 groups (53% lower in the HDAdApoAI group; Table) , there was only a small, statistically insignificant difference between paired HDAdApoAIand HDAdNull-treated arteries (5%; P=0.9; Figure 4D ; Table) . Finally, although HDAdApoAI-treated arteries had significantly lower amounts of intimal lipid, macrophages, and SMC, the percentage of intimal area occupied by each of these lesion components (and by T cells) did not differ significantly between paired HDAdApoAI-treated and HDAdNull-treated arteries (P=0.2-0.9; Table) .
We also used mass spectrometry to measure free and esterified cholesterol in extracts of full-thickness artery segments ( Figure V and Table I in the online-only Data Supplement). Free cholesterol content was 25% lower in the group of HDAdApoAI arteries than the group of HDAdNull arteries, with essentially no difference between paired arteries in the same rabbits (1% difference; P=0.5). Median cholesteryl ester and total cholesterol content were ≈60% lower in the group of HDAdApoAI arteries, but the difference between paired arteries was much less (6% and 9% decreases in paired HDAdApoAI arteries, respectively; P=0.4 for both). The median percentage of esterified cholesterol was almost identical between the 2 groups, with a median 7% reduction in paired HDAdApoAI arteries (P=0.2).
HDAdApoAI Alters Lesion Inflammatory Markers and ABCA1 Expression
Compared with the vascular media and adventitia, intimal lesions contained relatively high levels of expression of VCAM-1 (vascular cell adhesion protein-1) and ICAM-1 (intercellular adhesion molecule-1; Figure 2I , 2J, 2M, and 2N). VCAM-1 and ICAM-1 were expressed both in luminal EC and deeper in the intima. Compared with the group of HDAdNull-infused arteries, HDAdApoAI reduced median intimal VCAM-1 staining by 40%, whereas median intimal ICAM-1 staining was reduced by 56%. Within-rabbit paired analyses showed reductions in both intimal VCAM-1 and ICAM-1 staining in HDAdApoAI-treated carotids compared with their contralateral HDAdNull-treated controls, with a median decrease of 36% for VCAM-1 and 29% for ICAM-1 (P=0.03 and P=0.07, respectively; Figure 5A and 5B; Table) . Neither the percentage of intimal area stained for VCAM-1 nor the percentage of intimal area stained for ICAM-1 differed significantly between HDAdApoAI-treated carotid arteries and their paired HDAdNull-treated arteries (P=0.5 and P=0.3, respectively; Table) .
Using mRNA extracted from full-thickness artery segments ( Figure II in the online-only Data Supplement), we measured levels of mRNA for 2 atherogenic cytokines: TNF-α (tumor necrosis factor-α) and MCP-1 (monocyte chemoattractant protein-1). Median mRNA levels of TNF-α and MCP-1 were reduced by 44% and 36%, respectively, in the group of HDAdApoAI-treated carotids versus the group of HDAdNull-treated carotids. Paired analyses showed lower TNF-α levels in HDAdApoAI-treated carotids compared with their contralateral controls, with a median reduction of 39% (P=0.06; Figure 6A ; Table II in the online-only Data Supplement). The paired analyses also showed lower MCP-1 expression in HDAdApoAI-treated carotids, with a median decrease of 13% (P=0.1; Figure 6B ; Table II in the onlineonly Data Supplement). We also attempted to measure mRNA for the atheroprotective cytokine IL-10 (interleukin-10); however, IL-10 mRNA was detectable in only a few of the arteries, precluding a meaningful comparison.
Because macrophage phenotype is affected by apo A-I protein injection 37, 38 and because changes in macrophage phenotype can alter atherosclerosis progression, 39, 40 we quantified mRNA-encoding markers of rabbit M1 and M2 macrophages. 41 The M2 markers MRC1 (mannose receptor C-type 1) and ARG1 (arginase 1) were both 20% lower in the group of HDAdApoAI-treated arteries compared with the group of HDAdNull-treated arteries. Paired analyses revealed a median decrease in MRC1 and an increase in ARG1 (22% and 11%; P=0.2 and 0.7, respectively; Figure 6C and 6D; Table II in the online-only Data Supplement). The M1 macrophage marker IL-1β was decreased by 20% in the group of HDAdApoAI-treated arteries, with an 18% reduction in the paired analyses ( Figure 6E ; Table II in Finally, because lipid-free apo A-I initiates reverse cholesterol transport largely via interaction with ABCA1 (ATPbinding cassette subfamily A, member 1), we tested whether ABCA1 is expressed in the rabbit carotids. We measured ABCA1 mRNA in extracts of 48 of the 50 experimental arteries. ABCA1 mRNA was detected in all arteries, with 60% lower ABCA1 mRNA levels in the group of HDAdApoAItreated carotids compared with the group of HDAdNull-treated carotids ( Figure 
Discussion
We transduced carotid artery EC of hyperlipidemic rabbits with an apo A-I-expressing HDAd vector and tested whether expression of apo A-I could retard development of atherosclerosis over a 24-week period, despite persistent hyperlipidemia. Our major findings were (1) a single infusion of HDAdApoAI yielded apo A-I expression that persisted for at least 24 weeks in hyperlipidemic rabbits; (2) Because of the central role of apo A-I in mediating cholesterol efflux, several groups have developed therapies aimed at increasing plasma apo A-I levels or augmenting plasma apo A-I-like activity. These therapies, which include small molecules that increase apo A-I synthesis, apo A-I-mimetic peptides, and infusion of apo A-I protein, 17 have yielded promising results in animals and in small clinical trials. 13, 42, 43 However, none has shown benefit in a large human trial. Moreover, clinical implementation of these apo A-I-directed therapies is hindered by the short half-life of plasma apo A-I, a parenteral delivery requirement for most of the protein and peptide formulations, high cost, toxicity, and limited understanding of the mode of action of apo A-I-mimetic peptides. 17, 44 Apo A-I gene therapy has 2 major advantages over other apo A-I-directed therapies. First, a single dose of apo A-I gene therapy could potentially deliver apo A-I for years, [24] [25] [26] [27] obviating a need both for repeat dosing and for producing and purifying large amounts of apo A-I. Second, apo A-I gene therapy directs the synthesis and release of native apo A-I protein, eliminating the need to reconstitute apo A-I function with synthetic components. 44 Because of these advantages, several groups have developed apo A-I gene therapy and reported therapeutic effects in preclinical models. For example, adenovirus-mediated apo A-I gene therapy targeted to mouse liver increases plasma apo A-I levels, reduces atherosclerosis progression, and causes regression of atherosclerosis. [45] [46] [47] Another approach to apo A-I gene therapy includes ex vivo transduction of bone marrow cells with integrating apo A-I-expressing viral vectors such as retrovirus or lentivirus. The transduced bone marrow is then used to reconstitute lethally irradiated atherosclerosis-prone mice. [48] [49] [50] Using this approach, Ishiguro et al 48 and Tavori et al 49 showed that macrophage-mediated apo A-I gene therapy reduced atherosclerosis without affecting plasma HDL-C levels, suggesting that local vessel wall delivery of apo A-I is sufficient to achieve therapeutic effects. Unfortunately, neither of these gene therapy approaches is easily translated into a human therapy. Liver-directed gene therapy typically requires infusion of large amounts of vector, which can be toxic. 51 Because apo A-I is one of the most abundant native plasma proteins, 12 large amounts of vector would be required for liver-targeted gene therapy aimed at increasing plasma apo A-I. Moreover, vector-mediated expression of apo A-I in the liver downregulates endogenous apo A-I expression, potentially resulting in no net increase in plasma apo A-I. 46 In addition, expression of transgenes in the liver typically declines over time (likely because of cell turnover), requiring retreatment. 24, 45 In contrast, bone marrow-targeted gene therapy, in which stem cells are transduced with integrating . Data points are means for each artery; points from arteries in the same rabbit are connected by bars. Rabbits in which the HDAdApoAI-treated artery had a lower value than the contralateral HDAdNull-treated artery are indicated in black; rabbits in which the HDAdApoAI-treated artery had a higher value than the contralateral HDAdNull-treated artery are indicated in gray. P values are from Wilcoxon signed-rank test comparing HDAdApoAI-and HDAdNull-treated carotids in the same rabbit.
vectors, could provide lifelong apo A-I delivery. 48 However, bone marrow-mediated gene therapy would require myeloablative conditioning that-for humans-carries unacceptable costs and risks.
Because of these limitations of liver-targeted and bone marrow-targeted apo A-I gene therapy, we developed EC-targeted apo A-I gene therapy as an alternative approach. Delivery of apo A-I to the vessel wall from overlying EC has several theoretical advantages. First, apo A-I is delivered at high concentrations precisely where it is needed: adjacent to macrophages and SMCs in which lipid is accumulating. Basolateral secretion would deliver apo A-I directly to the intima; others have reported that ECs secrete apo A-I predominantly from their basolateral surface. 52 Apically secreted apo A-I would likely be transported across the endothelial monolayer via the same apical-to-basolateral transcytotic pathway through which plasma apo A-I is delivered to the subendothelium. 53 Second, when produced by EC, apo A-I is secreted in a lipid-free state, in which it is a superior stimulator of cholesterol efflux. 23 In contrast, apo A-I secreted by the liver is lipidated on secretion, decreasing its cholesterol-efflux capacity. 23, 54 Third, HDAd-mediated transgene expression in EC is inherently stable, lasting at least 48 weeks and likely far longer. 22, 55 Fourth, continuous apo A-I delivery from EC eliminates a need for vector-encoded apo A-I to circulate in plasma, in which it can be damaged by systemic inflammatory processes. 56, 57 Data presented herein supports the efficacy of vessel wall-targeted apo A-I gene therapy. HDAdApoAI-treated arteries had smaller lesions, less intimal lipid, and fewer intimal macrophages. The small number of HDAdApoAI-transduced cells (confined to a short segment of a single artery) and the paired study design exclude the possibility that these therapeutic effects are mediated by vector-mediated increases in plasma apo A-I (levels of which decreased during the course of the study).
We reported previously that transduction of rabbit carotid EC with HDAdApoAI significantly reduced atherosclerosis progression over a 4-week period. 22 In more recent work, we found that this same gene therapy approach tended to promote regression of established atherosclerotic lesions. 31 In relation to these earlier studies, results reported herein extend our work in important ways. Compared with the first study, in which treated lesions were limited to early fatty streaks that regressed spontaneously by 8 weeks, 22 we now show that apo A-I gene therapy durably (24 weeks) retards lesion growth. Moreover, the present study establishes that apo A-I gene Figure 6 . Expression of inflammation-related markers in carotid arteries. Rabbit carotid arteries were transduced with either a control vector (HDAdNull; Null) or an apo A-I (apolipoprotein A-I)-expressing vector (HDAdApoAI; ApoAI) and harvested 24 wk later. mRNA was measured, normalized to GAPDH (glyceraldehyde phosphate dehydrogenase) mRNA measured in the same extract, and expressed as arbitrary units (AU). A, TNF-α (tumor necrosis factor-α). B, MCP-1 (monocyte chemoattractant protein 1). C, MRC-1 (mannose receptor C-type 1; a M2 macrophage marker). D, ARG-1 (arginase-1; a M2 macrophage marker). E, IL-1β (interleukin-1β; a M1 macrophage marker). Data points are values for each artery; points from arteries in the same rabbit are connected by bars. Rabbits in which the HDAdApoAI-treated artery had a lower value than the contralateral HDAdNull-treated artery are indicated in black; rabbits in which the HDAdApoAI-treated artery had a higher value than the contralateral HDAdNull-treated artery are indicated in gray. P values are from Wilcoxon signed-rank test comparing HDAdApoAI-and HDAdNull-treated carotids in the same rabbit.
therapy can limit growth of more complex atherosclerotic lesions that contain SMCs and lipid and macrophages.
Compared with the second study, in which expression from HDAdApoAI in hyperlipidemic rabbits was measured for only 7 weeks, 31 we now show that apo A-I expression continues at a high level for at least 24 weeks, despite persistent hyperlipidemia. This is important because hyperlipidemia and atherosclerosis can increase EC loss and replication, 28, 29 and until now, we had shown durable HDAdApoAI expression only in chow-fed rabbits. 22, 58 In addition, in the second study, HDAdApoAI appeared ineffective in treating large intimal lesions that develop in a subgroup of highly atherosclerosis-prone rabbits. 31 In contrast, in the present study, apo A-I gene therapy uniformly prevented lesion growth in the most atherosclerosis-prone rabbits (Supplemental Figure VII in the online-only Data Supplement). We attribute the superior performance of apo A-I gene therapy in the present study to delivery of HDAdApoAI early in lesion development, versus delivery to existing lesions in the earlier study. 31 Apo A-I secreted from a single layer of EC may not sufficiently raise apo A-I levels deep within large pre-existing intimal lesions to achieve a therapeutic effect. Another possible explanation for efficacy in the present versus the former study is the difference in duration of treatment (24 versus 7 weeks); achievement of lesion regression may require >7 weeks of gene therapy. Taken together, our new results continue to show promise for HDAdApoAI-mediated gene therapy and support its further development as a therapy for human atherosclerosis.
In the present study, HDAdApoAI reduced intimal lesion size and intimal lipid and macrophages. These results are expected based on the ability of apo A-I to remove cholesterol from macrophages and incorporate it into particles that can remove cholesterol from the vessel wall. 59 HDAdApoAI also reduced the amount of intimal area occupied by SMC. This was unanticipated; however, it may reflect apo A-I-mediated removal of cholesterol from SMC that reduces SMC mass. 60 This explanation would be consistent with a growing recognition that many intimal foam cells are of SMC lineage. 61 Alternatively, decreased SMC content in the intima could reflect a lower rate of SMC migration or proliferation in apo A-I-treated arteries. 62, 63 As in our previous study, 31 the percentage of the intima occupied by lipid, total cells, or specific cell types was unchanged in HDAdApoAI-treated arteries. This is likely because apo A-I removes lipid from both macrophages and SMC, thereby reducing intimal volumes of lipid, macrophages, and SMC in equal proportions.
In addition to stimulating removal of cellular cholesterol, lipid-poor apo A-I produced by HDAdApoAI may reduce atherosclerosis via local anti-inflammatory actions. [64] [65] [66] These actions could include blocking cytokine-mediated upregulation of ICAM-1 and VCAM-1 67 ; blocking production of inflammatory cytokines (eg, MCP-1, IL-6, and TNF-α) and increasing production of anti-inflammatory cytokines (eg, IL-10) 38 ; stimulating an anti-inflammatory M2 phenotype in lesion macrophages; 37 and inhibiting M1 macrophage polarization. 68 Lipidpoor apo A-I can also reduce lipid raft content of inflammatory and other vascular cells, leading to redistribution of cytokine receptors out of lipid rafts and impaired transduction of inflammatory signals. 69, 70 Consistent with these models, we found large reductions in intimal VCAM-1 and ICAM-1 staining in HDAdApoAI-treated arteries. Reduced VCAM-1 staining is reassuring because apo A-I reliably reduces VCAM-1 expression in other settings. 21, 46, 71, 72 HDAdApoAI-transduced arteries also had lower levels of MCP-1 and TNF-α mRNA, although these reductions were of only borderline significance. Lack of statistical significance could be because of measurement of cytokine mRNA in whole vessel extracts, whereas most of the measurements that differed significantly between HDAdApoAI and control arteries were limited to the intima, a site where EC-secreted apo A-I would be expected to have its maximal effect. Dilution of a therapeutic intimal signal by noise from the media and (especially) the adventitia could also explain why Oil Red O staining of the intima showed that apo A-I therapy significantly reduced lipid, whereas mass spectrometry-based measurements of lipid in whole artery extracts showed only a trend toward reduced cholesterol in HDAdApoAI arteries. These hypotheses could be tested by measuring mRNA in intimal tissue isolated by laser capture microdissection, by removing the adventitia before extracting tissue lipids (see Figure 2F for an example of adventitial lipid), or by isolating intimal cells ex vivo and measuring their cholesterol content. 70 Removal of cellular cholesterol by apo A-I depends onand could be limited by-ABCA1 expression. 73 Because cellular cholesterol loading upregulates ABCA1 expression, 74, 75 we assumed that ABCA1 would be abundant in the carotid intima. Accordingly, ABCA1 immunoreactivity was present throughout the intima (including in foam cells) of both HDAdApoAIand HDAdNull-transduced arteries. However, ABCA1 mRNA was significantly lower in HDAdApoAI-transduced versus HDAdNull-transduced arteries. Lower expression of ABCA1 in HDAdApoAI-transduced arteries could be a consequence of elevated apo A-I expression, because both apo A-I and HDL3 (generated by apo A-I-mediated cholesterol efflux) can downregulate ABCA1 expression. [74] [75] [76] We found a smaller-but still significant-reduction in intimal ABCA1 protein levels in HDAdApoAI-transduced versus HDAdNulltransduced arteries. The smaller reduction in ABCA1 protein versus mRNA might result from stabilization of ABCA1 protein by apo A-I. 77, 78 Downregulation of ABCA1 mRNA and protein in HDAdApoAI arteries could limit the efficacy of apo A-I gene therapy if ABCA1 levels fall sufficiently that cholesterol efflux is impaired. However, the observed decreases in ABCA1 mRNA and protein in HDAdApoAI arteries were small, and the decrease in intimal ABCA1 protein disappeared when protein levels were normalized to intimal area. Moreover, this potential limitation has not prevented efficacy of apo A-I in several animal models of apo A-I gene therapy and germ-line transgenic overexpression. [45] [46] [47] [48] [49] [50] 79, 80 We were surprised that we did not find apo A-I protein in medium conditioned by explanted HDAdApoAI-transduced arteries. This was unanticipated because artery apo A-I mRNA levels in the present study were at least as high as in a recent study in which we detected apo A-I protein in explant culture medium of HDAdApoAI-transduced arteries (data not shown). 31 In the earlier study, we used DMEM with phenol red for the explant cultures, whereas in the present study, we omitted phenol red, but this seems unlikely to explain the difference. It is possible that apo A-I protein is present in explant culture media in the current study but is below the level of detection. A drop in apo A-I protein despite stable apo A-I mRNA could result from translational downregulation 81, 82 ; however, complete cessation of apo A-I translation seems unlikely. Detection of low levels of rabbit apo A-I protein in experimental samples by Western blotting has been a challenge for us, which we surmounted only recently by generation of new antibodies. 31 To develop a more sensitive assay for apo A-I protein, we recently used these antibodies to develop an ELISA. The ELISA detected purified rabbit apo A-I with excellent sensitivity but was much less sensitive for detection of apo A-I in rabbit plasma or artery explant culture medium (data not shown). Nevertheless, although we did not detect increased apo A-I protein in HDAdApoAI-infused arteries, numerous biologically plausible phenotypic changes in these arteries (decreases in lesion area, Oil Red O-stained area, macrophage area, SMC area, expression of VCAM-1, TNF-α, and ABCA1) strongly suggest that apo A-I protein is produced by HDAdApoAI.
In conclusion, we demonstrate that local vascular delivery of apo A-I can durably reduce development of atherosclerosis, even in a setting of severe hyperlipidemia. Challenges of preexisting human immunity to viral vectors and lack of efficient percutaneous methods for delivering vectors to EC must be overcome before apo A-I vascular gene therapy can be applied clinically, but progress is evident in both of these areas. 83, 84 We are optimistic that these challenges will be overcome and that local vascular delivery of apo A-I will become a complementary therapy to LDL lowering, leading to a further reduction in human atherosclerotic cardiovascular disease.
